FDA Brief

Warning letters Drugs

FDA warning letter to

Cosmetic Solutions, LLC

High riskIssued May 31, 2024Posted Jun 11, 2024Division of Pharmaceutical Quality Operations II

FDA warns Cosmetic Solutions over manufacturing failures and unapproved OTC drugs at Boca Raton plant.

What happened

FDA inspected the Boca Raton drug manufacturing facility from September 12 to 21, 2023. It found CGMP (current good manufacturing practice) failures, including inadequate quality-unit oversight, missing stability testing, weak supplier and incoming-material controls, manufacturing changes outside change control, a purified water system that failed microbial tests and was used in multiple batches, and cleaning validation that did not cover all products and equipment. FDA also found that labels and websites made drug claims for OTC products that are unapproved new drugs, and it called the company’s October 11, 2023 response inadequate.

What FDA found

  1. The quality unit did not provide adequate oversight and did not ensure written procedures were followed.

    21 CFR 211.22(d)
  2. Batches were not placed into the stability testing program as the company’s procedure required.

    21 CFR 211.166(a) and (b)
  3. The company did not establish the reliability of supplier test analyses and did not follow its procedure for incoming raw material sampling, inspection, and release.

    21 CFR 211.84(d)(2)
  4. Manufacturing changes were made outside the company’s change control procedure.

    21 CFR 211.100(a)
  5. The purified water system was not qualified, water failed microbial tests and was used in multiple batches, and cleaning validation did not cover all products and equipment, including equipment shared with cosmetics.

    21 CFR 211.100(a) and (b)
  6. FDA says the OTC products are unapproved new drugs because their labels make drug claims and they are not generally recognized as safe and effective or covered by an FDA-approved application.

    FD&C Act sections 301(d) and 505(a), 21 U.S.C. 331(d) and 355(a)

What FDA wants

FDA tells the company to respond in writing within 15 working days with corrective actions to prevent recurrence. It asks for comprehensive assessments and remediation plans for the quality unit, stability program, material system, change management, water system, and cleaning validation, and recommends a qualified CGMP consultant.

Who should pay attention

  • brands that buy OTC drug products from this contract manufacturer
  • companies sharing drug and cosmetic manufacturing equipment
  • quality teams responsible for water systems and supplier qualification

This is a summary. Read the original letter on fda.gov.

Similar letters to other companies

  1. Natural Essentials, Inc.

    FDA warns Natural Essentials over OTC drug manufacturing violations, including inadequate failing test result investigations and missing component identity tests.

    High risk
  2. Shenzhen Benliju Biotech Co., Ltd.

    FDA: Shenzhen Benliju Biotech released OTC drugs labeled sterile without sterility testing or process validation.

    High risk
  3. LGM Pharma Solutions, LLC

    FDA warned LGM Pharma Solutions over manufacturing-quality failures in failing-result investigations and process validation for tablets, including a recalled product.

    High risk
  4. Penn Herb Company, Ltd.

    FDA warned Penn Herb Company over CGMP violations and an undeclared tree-nut allergen in three dietary supplements.

    High risk